Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prelude TherapeuticsPRLD -6.46%26 Cash-to-Debt is 8.60 as of Jun. 2026, which is 93% below its 10-year median of 118.36. GuruFocus rates PRLD with a GF Score™ of 26/100. The stock has 5 warning signs investors should review. Among 1,399 Biotechnology companies, Prelude Therapeutics ranks better than 52.97% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Prelude Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2026 was 8.60.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Prelude Therapeuticscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Prelude Therapeutics's Cash-to-Debt or its related term are showing as below:
PRLD'
s Cash-to-Debt Range Over the Past 10 Years
Min: 3.08 Med: 118.36 Max: No Debt
Current: 8.6
During the past 8 years, Prelude Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 3.08. And the median was 118.36.
PRLD's Cash-to-Debt is ranked better than 52.97% of 1399
companies
in the Biotechnology industry
Industry Median: 6.49
vs PRLD: 8.60
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Prelude Therapeutics Cash-to-Debt Related Terms
Prelude Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Prelude Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Prelude Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prelude Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prelude Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Prelude Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prelude Therapeutics (PRLD) has a Cash-to-Debt of 8.60 as of Jun. 2026. This is 93% below median its historical median of 118.36. Over the past decade, Prelude Therapeutics' Cash-to-Debt has ranged from 3.08 to 10,000.00. According to the industry distribution chart, Prelude Therapeutics ranks #658 out of 1399 companies in the Biotechnology industry, placing it in the top 47%.
Is Prelude Therapeutics' Cash-to-Debt too high?
Prelude Therapeutics' current Cash-to-Debt of 8.60 is 93% below median its 10-year median of 118.36. Over the past 10 years, this metric has ranged from a low of 3.08 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.49. Prelude Therapeutics' value of 8.60 is 32.5% above this industry median. Based on the distribution chart, Prelude Therapeutics ranks #658 out of 1399 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Prelude Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Prelude Therapeutics' Cash-to-Debt compare to PROK and ZNTL?
According to the Biotechnology industry distribution chart, Prelude Therapeutics ranks #658 out of 1399 companies for Cash-to-Debt. This puts Prelude Therapeutics in the upper half of its industry. The industry median Cash-to-Debt is 6.49. Prelude Therapeutics' value of 8.60 is 32.5% above this benchmark. Historically, Prelude Therapeutics' own Cash-to-Debt has ranged from 3.08 to 10,000.00 over the past decade. While the company's 10-year median is 118.36 vs. the industry median of 6.49, Prelude Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.49, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prelude Therapeutics's current Cash-to-Debt of 8.60 is 32.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prelude Therapeutics's current Cash-to-Debt is 8.60, which is 93% below median its own 10-year median of 118.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prelude Therapeutics stock overvalued right now?
Prelude Therapeutics (PRLD) has a current Cash-to-Debt of 8.60. The current Cash-to-Debt is 8.60, which is 93% below median its 10-year median of 118.36 and 32.5% above the Biotechnology industry median of 6.49. Prelude Therapeutics' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Prelude Therapeutics (PRLD), the current Cash-to-Debt is 8.60 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
26GF Score
Get the complete analysis for PRLD
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRLD has been successfully added to your 
